Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stevenage, UK, June 20 2013 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation (OI) bioscience campus, is pleased to announce that Johnson & Johnson Innovation has established an in-house Partnering Office on site. This relationship represents an important addition to the incubator’s entrepreneurial community. Through it, experts from the London Innovation Centre of Johnson & Johnson Innovation will be able to access and influence new areas of technology and product development, via SBC’s tenants, stakeholders and innovation network. A leading healthcare player, the Johnson & Johnson Family of Companies spans the pharmaceutical, medical device and diagnostics and consumer markets globally.
The London Innovation Centre is part of Johnson & Johnson Innovation, which focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across the company’s healthcare businesses, building relationships with academia, bioscience organisations and venture capital firms. These types of organisations are well represented in SBC’s innovation network. Stevenage Bioscience Catalyst’s stakeholders are GlaxoSmithKline, the Wellcome Trust, the Department of Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency.
Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst, said ‘We are delighted that Johnson &Johnson Innovation in the UK has decided to establish a partnering office at SBC, in a natural extension of our unique pharma incubation model. Innovation is a collaborative and serendipitous process and SBC is working with partners like this to create an environment where it can flourish. With its broad expertise, J&J is a great partner as we look to catalyse innovation across healthcare, from drug discovery to convergent medical technologies.’
For more information, please contact:
Stevenage Bioscience Catalyst
Martino Picardo, CEO +44 (0)1438 906906
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
comms@stevenagecatalyst.com
Please reply with ‘unsubscribe’ in the subject box if you no longer wish to hear from Stevenage Bioscience Catalyst
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com.
About Johnson & Johnson Innovation
Find out more about Johnson & Johnson Innovation and its Innovation Centres at http://www.jnjinnovation.com
About Open Innovation
Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and expertise. OI is characterised by highly effective use of connections and networks to exchange knowledge and ideas, external partners being involved at all stages of product development, equitable win-win business relationships, and new business models to maximise the value of intellectual property and other assets. Examples in various sectors have shown that the benefits of OI include reduced time to market for new products and services, access to new markets, improved innovation success rates and increased profits. SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs with an active network consisting of GlaxoSmithKline and its other stakeholders, academia, charities, other businesses and funding bodies. The term ‘Open Innovation’ and related research into its practice have been developed extensively by Professor Henry Chesbrough, Executive Director of the Program in Open Innovation at the University of California, Berkeley (http://openinnovation.berkeley.edu).
About Stevenage Bioscience Catalyst’s stakeholders
Stevenage Bioscience Catalyst’s stakeholders are GlaxoSmithKline (www.gsk.com), the Wellcome Trust (www.wellcome.ac.uk), the Department of Business, Innovation and Skills (www.bis.gov.uk), the Technology Strategy Board (www.innovateuk.org) and the former East of England Development Agency (http://www.eeda.org.uk/)
Emma Palmer Foster
Strategic Communications Consultant
Stevenage Bioscience Catalyst
m: +44 (0) 7880 787185
http://www.stevenagecatalyst.com/
@SteBioCat
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire SG1 2FX
Help employers find you! Check out all the jobs and post your resume.
